Systematic review reveals pharmacist barriers to deprescribing, suggesting structural changes are necessary for improvement.
There was a variety of practice settings and deprescribing focuses (i.e., potentially inappropriate medications, benzodiazepines, opioids) in the included studies. These differences may limit the applicability of findings to specific practice sites or medication classes. Nevertheless, the findings of this study highlight that structural changes such as advancing pharmacist scope of practice, redesigning renumeration models, integrating healthcare systems and improving the data sharing are required to optimize pharmacist's role in deprescribing.
No takes yet. Share an insight, caveat, or question.
Bolt et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: